Tag: Orphan Drug Designation Pathway Analysis
2024 Advancements: AAV Vector Optimization, CRISPR Off – Target Mitigation, Orphan Drug Pathways, and Rare Disease Biomarker Validation
In 2024, the biotech industry is witnessing remarkable advancements in gene therapy and rare disease treatment. According to Signal Transduction and Targeted Therapy 2024 and a SEMrush 2023 Study, AAV vector optimization, CRISPR off – target mitigation, orphan drug pathways, and rare disease biomarker validation are at the forefront. Premium techniques in AAV vector engineering